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-Taurine is a beta-amino acid found in very high concentration in the heart. Depletion of these intracellular stores results in the development of cardiomyopathy, thought to be mediated by abnormal sarcoplasmic reticular (SR) Ca 2ϩ transport. There is also evidence that taurine directly alters the Ca 2ϩ sensitivity of myofibrillar proteins. Major regulators of SR Ca 2ϩ ATPase (SERCA2a) are the phosphorylation status of a regulatory protein, phospholamban, and SERCA2a expression, which are diminished in the failing heart. The failing heart also exhibits reductions in myofibrillar Ca 2ϩ sensitivity, a property regulated by the phosphorylation of the muscle protein, troponin I. Therefore, we tested the hypothesis that taurine deficiency leads to alterations in SR Ca 2ϩ ATPase activity related to reduced phospholamban phosphorylation and expression of SERCA2a. We found that a sequence of events, which included elevated protein phosphatase 1 activity, reduced autophosphorylation of CaMKII, and reduced phospholamban phosphorylation, supports the reduction in SR Ca 2ϩ ATPase activity. However, the reduction in SR Ca 2ϩ ATPase activity was not caused by reduced SERCA2a expression. Taurine transporter knockout (TauTKO) hearts also exhibited a rightward shift in the Ca 2ϩ dependence of the myofibrillar Ca 2ϩ ATPase, a property that is associated with an elevation in phosphorylated troponin I. The findings support the observation that taurine deficient hearts develop systolic and diastolic defects related to reduced SR Ca 2ϩ ATPase activity, a change mediated in part by reduced phospholamban phosphorylation. taurine; cardiomyopathy; protein phosphorylation; troponin I; phospholamban; sarcoplasmic reticular Ca 2ϩ ATPase activity TAURINE is a beta-amino acid found in very high concentration in excitable tissues. The maintenance of these high intracellular levels of taurine depends upon both dietary and biosynthetic sources of the amino acid (15) . Because taurine biosynthesis is largely restricted to the liver, taurine levels in the heart depends upon a taurine transporter, which is located on the cell membrane and accumulates taurine against a large taurine gradient; normal cytosolic taurine levels range from 1 to 30 mM while plasma concentrations in most mammals vary from 40 to 60 M (48). Large amounts of taurine are found in the mitochondria, where the amino acid conjugates with a specific uridine residue of several tRNAs (45) . The most widely studied conjugation reaction involves a folate-dependent reaction leading to the formation of 5-taurinomethyluridine in the wobble position of tRNA Leu(UUR) (37) . The expression of one of the mitochondria encoded proteins (ND6) is impaired in the taurine deficient heart (18) . Because ND6 is a necessary component of complex I of the electron transport chain, taurine deficiency leads to reduced respiratory chain function and oxidative metabolism (18) . The defective electron transport chain is also a major source of superoxide anion and other reactive oxygen species (ROS), which commonly contribute to myocardial dysfunction (18) . In addition, taurine deficiency also results in a dramatic shift in energy metabolism by the heart, as the rate of glycolysis is significantly increased but glucose oxidation is dramatically reduced, resulting in significant increases in lactate production and the lactate/pyruvate ratio (30) . High-energy phosphate levels also decline, as oxygen consumption is reduced.
The taurine deficient phenotype resembles the phenotype of the mitochondrial disease, MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) (37), which is caused by a mutation in tRNA Leu(UUR) that diminishes the formation of 5-taurinomethyluridine-tRNA Leu(UUR) . Both the mitochondrial disease and animal models of taurine deficiency develop dilated cardiomyopathy, which are characterized by defects in both systolic and diastolic function (16, 32, 34) .
Although the heart is resistant to major changes in taurine content, large amounts of taurine leave the heart during an ischemia-reperfusion or hypoxic insult (36) . Because damage to the heart during a myocardial infarction renders the heart susceptible to the development of congestive heart failure, it has been suggested that taurine contributes to the development of heart failure (36) . In support of this hypothesis, it has been shown that taurine deficient animals develop a cardiomyopathy (16, 32, 34) . Moreover, taurine treatment improves contractile function and reduces mortality in several animal models of heart failure (17) . Taurine is also therapeutically effective in diminishing the severity of congestive heart failure and therefore has been approved for the treatment of heart failure in Japan (3). Although taurine attenuates the actions of angiotensin II and norepinephrine (17) , its effect on excitation-contraction coupling has not been adequately studied. Hence, the present study tests the hypothesis that taurine deficiency in the heart of taurine transporter knockout (TauTKO) mice produces a cardiomyopathy associated with altered calcium transporter activity correlating to the reduction in the amplitude and prolongation of the calcium transient. These animals develop a unique dilated cardiomyopathy, in which cardiomyocyte size is reduced (16, 35) .
METHODS
Animal care. The experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of South Alabama College of Medicine. TauTKO and littermate mice were maintained under a controlled environment (22°C, 12:12-h light-dark cycles, food and water ad libitum). The mice were genotyped by PCR and used in the experiment at 3-6 mo of age.
To produce the TauTKO mouse, the taurine transporter gene (TauT) transcript was truncated so that it included exon 5 but not exons 2-4. This was achieved by replacing exons 2-4 with a targeting vector that confers neomycin resistance (16) . The taurine content of the wild-type and TauTKO hearts were 30 mM and undetectable levels, respectively (16) .
Western blot analyses. Hearts from 3-to 6-mo-old wild-type and TauTKO mice were homogenized in RadioImmuno Precipitation Assay lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Nonidet P40, 1% sodium deoxycholate, 1% Triton X-100, 0.5% SDS, 0.1% EDTA, 1 mM PMSF) supplemented with protease inhibitors (1:100 dilution of protease inhibitor cocktail, Thermo Scientific, Rockford, IL), 1 mM NaF, 1 mM sodium orthovanadate, and 5 mM betaglycerophosphate. After centrifugation for 20 min at 10,000 g, supernatant samples were mixed with 5X electrophoresis buffer (1.25 mM Tris, pH 6.8, containing 1% SDS, 10% glycerol and 5% mercaptoethanol) and then boiled for 3 min. The samples were then subjected to 10 -15% SDS-PAGE. After electrophoresis, the proteins were transferred to nitrocellulose membrane, which were then blocked. To complete the Western blot procedure, the membranes were incubated with the chosen antibody followed by a secondary antibody. The Western blot was developed and visualized by enhanced chemiluminescence. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to normalize protein loading.
Enzyme assays. Calcium calmodulin-dependent protein kinase II (CaMKII) was assayed according to the method of Chang et al. (5) . Protein phosphatase 1 and 2A subfamilies were assayed using 32 Pphosphorylase-a as substrate as described by Ahmed et al. (1) . The protein phosphatase 1B subfamily was assayed according to the method of Shenolikar and Ingebritsen (40) using 32 P-phosphorylase kinase as substrate. The protein phosphatase 2C subfamily was assayed according to the method of Allo and Schaffer (2) using 32 Pphosphorylase kinase-a as substrate.
Calcium sensitivity of myofibrils. Myofibrils from TauTKO and wild-type mice were prepared according to the method of Pierce and Dhalla (33) . Mg 2ϩ -dependent ATPase activity was determined after addition of myofibrillar proteins to an imidazole reaction buffer (pH 6.8) containing 2 mM MgCl2, 2 mM Na2ATP, 10 mM NaN3, 1.6 mM EGTA, and 50 mM KCl. The reaction was terminated with 12% trichloroacetic acid and after centrifugation, the phosphate content of the reaction mixture determined spectrophotometrically. The reaction was repeated at various concentrations of free Ca 2ϩ , where free [Ca 2ϩ ] was calculated according to the method of Katz et al. (19) . Quantitative real time PCR. RNA was isolated from wild-type and TauTKO hearts using the PrepEase RNA spin kit (USB). Quantitative real-time PCR was then performed using the iScript One-Step RT-PCR kit with SYBR Green (Bio-Rad). All primers were designed by Beacon program to amplify 100-to 250-bp sequences within the specific sequences of the experimental genes. Primer sequences for SERCA2a were 5=-ATCCAGGTCTGGAGGATTGA-3= (forward) and 5=-AGATGGTCCTGGCAGAC-3= (reverse) and for 28s rRNA were 5=-TCGGCTCTTCCTATCATT-3= (forward) and 5=-GCAA-CAACACATCATCAG-3= (reverse).
SR Ca 2ϩ ATPase activity. Sarcoplasmic reticular (SR) protein was isolated from hearts according to the method of Ganguly et al. (10) . Briefly, the ventricular tissue was homogenized in medium containing 10 mM NaHCO3, 5 mM NaN3, and 15 mM Tris-HCl (pH 6.8). The homogenate was then centrifuged for 20 min at 10,000 g and the resulting supernatant was centrifuged at 40,000 g for 45 min. The resulting pellet was suspended in medium containing 0.6 M KCl and 20 mM Tris-HCl (pH 6.8) and then recentrifuged at 40,000 g for 45 min; the final pellet was suspended in medium containing 0.25 M sucrose and 20 mM Tris-HCl (pH 6.8). The protein concentration of the SR preparation was determined and the samples were assayed for SR Ca 2ϩ ATPase activity at a protein concentration of 30 g/0.5 ml assay. Basal Mg 2ϩ -dependent ATPase was determined at 37°C in a reaction mixture containing (in mM) 100 KCl, 5 MgCl2, 5 K-oxalate, 5 Na-azide, 20 Tris-HCl, 0.2 EGTA and SR protein. The reaction was initiated by adding 5 mM Tris-ATP and terminated by adding 500 l of 12% cold trichloroacetic acid and keeping the samples on ice for 10 min. Each sample was centrifuged, and the supernatant was assayed for phosphate content according to the method of Fiske and Subbarow (39a). Total ATPase activity was determined in medium supplemented with free Ca 2ϩ concentrations of 0, 3.2 ϫ 10 Ϫ7 M, and 10
Ϫ6
M. Ca 2ϩ -dependent SR ATPase activity was defined as the difference between the values obtained in the presence and absence of calcium.
Statistical analyses. The statistical analysis was carried out using the Statmost Software Package. In most experiments, two variables were compared, evaluated using the Student's t-test. Group comparisons were evaluated by analysis of variance followed by comparisons of means using Newman-Keuls post hoc test.
RESULTS

Effect of taurine deficiency on sarcoplasmic reticular Ca 2ϩ
handling. Figure 1 shows that the activity of SR Ca 2ϩ -dependent ATPase was significantly reduced at the Ca 2ϩ concentration of 3.2 ϫ 10 Ϫ7 M (pCa ϭ 6.5), which is close to the K m of the enzyme for Ca 2ϩ . On the other hand, taurine deficiency had no effect on enzyme activity at a Ca 2ϩ concentration of 10 ATPase activity, mRNA and protein content of SERCA2a in wild-type and TauTKO hearts were evaluated using real-time PCR and Western blot analyses, respectively. No significant difference in either the mRNA or protein content of SERCA2a from wild-type and TauTKO hearts was detected ( Fig. 2A) , ruling out a role of impaired SERCA2a expression in the development of taurine deficient cardiomyopathy.
Another factor influencing SR Ca 2ϩ ATPase activity of the failing heart is phospholamban activity. Both an elevation in the phospholamban/SERCA2a protein ratio and a decrease in the phosphorylation state of phospholamban increase the ability of phospholamban to inhibit the activity of the SR Ca 2ϩ pump (6, 9) . In the failing heart, the elevation in phospholamban activity is commonly caused by both an upregulation of phospholamban and a decrease in its phosphorylation state. However, as seen in Fig. 2, A and B, taurine deficiency had no effect on either SERCA2a or phospholamban content, indicating that the decline in SR Ca 2ϩ pump activity in the TauTKO heart was not caused by a change in the phospholamban/ SERCA2a protein ratio. Rather, compared with age-matched, wild-type cohorts, the levels of phosphorylated phospholamban were significantly reduced in the TauTKO heart (Fig. 2B) , revealing that the inhibitory actions of phospholamban are enhanced in the TauTKO heart despite the presence of normal phospholamban and SERCA2A levels (24) .
The phosphorylation state of phospholamban in the failing heart is largely dependent upon the balance between the rates of phospholamban phosphorylation catalyzed by calcium, calmodulin-dependent protein kinase II (CaMKII) and phospholamban dephosphorylation by protein phosphatase 1 (pp1), as the regulation of phospholamban by cAMP-dependent protein kinase (PKA) remains largely unchanged in the failing heart (29, 31) . In agreement with its status in the failing heart, CaMKII activity is decreased 50% in taurine deficient cardiomyopathy while PKA activity is unaffected (Fig. 3A) . Of the two subgroups of protein phosphatases in the heart, taurine deficiency is associated with a 90% increase in protein phosphatase 1 while the activity of protein phosphatase 2 is identical in wild-type and TauTKO hearts (Fig. 4, A and B) . A mechanism by which elevations in pp1 activity can diminish CaMKII activity is by decreasing the phosphorylation state of the autophosphorylation site (Thr286/287) of CaMKII. In support of this hypothesis, it was found that the phosphorylation state of Thr287/286 is reduced in the TauTKO heart relative to that of the wild-type heart (Fig. 3B) .
Reduced Ca 2ϩ sensitivity of myofibrillar proteins of TauTKO heart. Steele et al. (43) (Fig. 5) . Because myofibrillar Ca 2ϩ sensitivity is regulated by the phosphorylation of the muscle protein troponin (20, 26) , the effect of taurine deficiency on total and phosphorylated troponin I was determined. While the troponin I content of TauTKO and wild-type hearts was unchanged, there was 30% more phosphorylated troponin I in TauTKO hearts than in their wild-type cohorts (Fig. 6) . Of the two protein kinases (protein kinase A and C) that commonly alter the phosphorylation state of troponin I, only protein kinase C (PKC) is affected by taurine deficiency. As seen in Fig. 7 , the cytosolic and membrane content of PKC␦ are elevated in TauTKO hearts relative to that of the wild-type heart. The membrane content of PKCε is also increased in the TauTKO heart, but the cytosolic content of PKCε declines, suggesting that taurine deficiency leads to a translocation of the isoform from the cytosol to the membrane Fig. 2 . Modulation of SERCA2a, phospholamban (PLB), and phosphorylated phospholamban (PLB-P) by taurine deficiency. A: hearts of wild-type and TauTKO hearts were homogenized in RIPA lysis buffer (pH 8.0). After centrifugation, the samples were subjected to SDS-PAGE electrophoresis. SERCA2a content was determined by Western blot analysis. Values shown represent means Ϯ SE of 3-4 hearts. All values are normalized relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels. B: samples for Western blot analysis were prepared according to the method described under A. Total phospholamban and phosphorylated phospholamban content were determined by Western blot analysis. The content of total phospholamban was identical in wild-type and TauTKO hearts while taurine deficiency was associated with a reduction in phosphorylated phospholamban content. Values for phosphorylated phospholamban represent means Ϯ SE of 3-4 hearts. *Significant difference between the phosphorylated phospholamban content of wild-type and TauTKO hearts (P Ͻ 0.05). All values are normalized relative to GAPDH levels. fraction, a change usually associated with the activation of the isoform. No significant changes were detected in the other three PKC isoforms (PKC␣, PKC␤ 2 , and PKC) examined.
DISCUSSION
A major finding of the present study is that taurine deficiencymediated alterations in the activities of both protein phosphatase 1 (pp1) and CaMKII appear to reduce the phosphorylation state of phospholamban, which in turn decreases the activity of the SR Ca 2ϩ ATPase. The decrease in SR Ca 2ϩ ATPase activity, which occurs at physiologically relevant Ca 2ϩ concentrations, appears to contribute to prolongation of the relaxation phase of the Ca 2ϩ transient and to diastolic dysfunction of the TauTKO heart (38). These changes assume pathological significance in MELAS (37) and the ischemic heart, the former associated with a defect in taurine conjugation and the latter being a taurine deficient condition (36) .
The concept that taurine is capable of regulating the phosphorylation state of cardiac proteins was originally introduced by Lombardini (21) , who found that taurine deficiency in- Fig. 3 . Reduction in myocardial CaMKII autophosphorylation and activity by taurine deficiency. Protein extracts of wild-type and TauTKO hearts were prepared according to the method of Fig. 2A . A: CaMKII activity was assayed in a reaction mixture containing or lacking trifluoperazime, an inhibitor of CaMKII. Values shown represent means Ϯ SE of 5-6 hearts. *Significant difference between wild-type and TauTKO hearts (P Ͻ 0.05). B: the content of autophosphorylated CaMKII (phosphorylated site on Thr286/287) was determined by Western blot analysis. Fig. 4 . Effect of taurine deficiency on protein phosphatase 1 activity. Protein extracts of wild-type and TauTKO hearts were prepared according to the method of Fig. 2 . A: protein phosphatase 1 (PP1) activity was performed using 32 P-phosphorylase-a as substrate in medium containing or lacking inhibitor-2. Protein phosphatase 1 represents inhibitor-2 sensitive phosphatase activity. Values shown represent means Ϯ SE of 4 -6 hearts. *Significant difference between the wild-type and TauTKO hearts (P Ͻ 0.05). B: protein phosphatase 2C (PP2C) activity is assayed in buffer containing 10 mM magnesium acetate using 32 P-phosphorylase kinase as substrate. Values shown represent means Ϯ SE of 4 -6 hearts. creases the phosphorylation state of a 44-kDa mitochondrial protein, which he eventually identified as pyruvate dehydrogenase. However, little information is available on the regulatory enzymes involved in the modulation of protein phosphorylation by taurine. The present study reveals that taurine deficiency is associated with a reduction in CaMKII activity and elevations in the activities of PKC-␦, PKC-ε, and protein phosphatase 1 (pp1).
The activity of pp1 is regulated by a complex series of phosphorylation reactions involving PKA, PKC-␣, phosphatase 2, CaMKII, and pp1 inhibitors (28) . In hypertrophic and failing hearts, pp1 activity is elevated because of increased expression of pp1 and decreased expression of inhibitor 1 (12, 51) . Interestingly, myocardial unloading, which leads to cardiac atrophy rather than hypertrophy, is also associated with an elevation in pp1 activity. Hence, it has been suggested that pp1 activity is regulated by the initiation of the fetal gene program in response to stress (39) . Accordingly, it is logical to conclude that enhanced pp1 expression is responsible for the elevation in pp1 activity in the TauTKO heart.
Relationship between pp1, CaMKII, and phospholamban in TauTKO heart. PKA and Ca 2ϩ -calmodulin dependent protein kinase II (CaMKII) serve as the dominant regulators of phospholamban phosphorylation and SR Ca 2ϩ ATPase activity (27) . In the TauTKO heart, PKA activity is normal while the activity of CaMKII is depressed, raising the possibility that the decrease in the phosphorylation state of phospholamban might be caused by a reduction in CaMKII activity.
CaMKII contains a catalytic and a regulatory domain, the latter of which contains an autoinhibitory domain that contains a pseudosubstrate sequence that is capable of interacting with the active site and blocking enzyme activity. The binding of Ca 2ϩ /calmodulin to the regulatory domain of the enzyme activates the enzyme by disrupting the interaction between the autoinhibitory and catalytic domains. It also allows the autophosphorylation of the enzyme at Thr286/287, which both increases the affinity of the enzyme for Ca 2ϩ /calmodulin and ensures elevated activity even in the absence of Ca 2ϩ /calmodulin (7) . Like autophosphorylation at Thr286/287, oxidation of Met281/282 converts the enzyme into a Ca 2ϩ /calmodulinindependent form with catalytic activity (7). According to Huke and Bers (14) , enhanced autophosphorylation of CaM-KII at Thr286/287 increases CaMKII activity, as represented by an elevation in phospholamban phosphorylation at Thr17. Conversely, diminished autophosphorylation of CaMKII at Thr286/287 and the resulting decline in CaMKII activity of the TauTKO heart is associated with a reduction in the phosphorylation of the CaMKII substrate, phospholamban Thr17 (Fig. 2B) .
Huke and Bers (14) found that autophosphorylation of CaM-KII at Thr286/287 is regulated by pp1. In the presence of a pp1 inhibitor, the autophosphorylation of CaMKII and catalytic activity of paced ventricular cardiomyocytes increased, leading to enhanced phospholamban phosphorylation. In the present study, taurine deficiency led to an increase in pp1 activity, which was associated with a decrease in the autophosphorylation of CaMKII and the phosphorylation of phospholamban. This sequence of events in the TauTKO heart is consistent with the view that an increase in pp1 activity reduces the autophosphorylation of CaMKII at Thr286/287, which in turn leads to a reduction in the phosphorylation of phospholamban at Thr17 and ultimately a reduction in SR Ca 2ϩ ATPase activity. However, it is relevant that pp1 can also bypass CaMKII and directly dephosphorylate phospholamban (4) .
Role of CaMKII, phospholamban, and SR Ca 2ϩ ATPase in TauTKO and failing hearts. CaMKII regulates multiple events involved in contractile function and ventricular remodeling, including SR Ca 2ϩ leakage (8, 25, 47) , hypertrophic gene expression and signaling (7, 23) , apoptosis (7, 47) , arrhythmias (7, 8, 46) , and high-energy phosphate metabolism (22) . Therefore, it is not surprising that CaMKII activity is elevated in most models of heart failure (50). However, taurine deficiency leads to the development of a cardiomyopathy despite a reduction in CaMKII activity. The basis for this apparent discrepancy is unclear although several complicating factors cloud the resolution of CaMKII's role in heart failure. First, CaMKII alters multiple events in the heart, with the importance of each event dependent upon the state of the failing heart. In the case of the TauTKO heart, autophosphorylation of CaMKII is reduced in the TauTKO heart; therefore, contractile function is influenced more by the phosphorylation state of the CaMKII substrate, phospholamban, rather than the effect of CaMKII on SR Ca 2ϩ leakage, apoptosis, and hypertrophic signaling. Second, both taurine and CaMKII are compartmentalized within the cell. Any change in the distribution of these regulators can affect contractile function. For example, Netticadan et al. (31) found that heart failure had little effect on CaMKII activity in the cytosol but had major differences in CaMKII in the sarcoplasmic reticulum. They suggested that the decrease in SR CaMKII activity might contribute to impaired SR function of the failing heart. Third, there are four major isoforms of CaMKII, with each isoform group containing multiple sub- groups. Major differences in the properties of the isoforms have been reported, which can influence the role of the enzyme in the failing heart (11, 41) . Downregulation of SERCA2a expression is a common feature of most models of heart failure, with some reporting either an increase or no change in phospholamban content (24, 26 -28) . However, the effect of heart failure on the phosphorylation status of phospholamban remains controversial. While some investigators observe a decrease in phospholamban phosphorylation secondary to the downregulation of the ␤-adrenergic system and an increase in protein phosphatase 1 activity, other investigators observe either an increase or no change in phospholamban phosphorylation (27) . The differences in the phosphorylation status of phospholamban appear to be dependent upon the model of heart failure and the stage of development. Thus it is not surprising that the TauTKO heart exhibits differences from other models of heart failure (no change in phospholamban and SERCA2 expression and reduced phospholamban phosphorylation), as taurine deficiency not only alters the activity of the protein kinases and protein phosphatases, but also modulates both [Ca 2ϩ ] i and the Ca 2ϩ dependence of the SR Ca 2ϩ ATPase. However, it is also possible that the activity of the SR Ca 2ϩ ATPase of the TauTKO heart might be altered by the oligomerization state of phospholamban (42) .
Regulation of myofilament Ca
2ϩ sensitivity in heart failure. End-stage heart failure in humans is associated with elevations in myofilament Ca 2ϩ sensitivity, while rodent models of heart failure are usually associated with reduced Ca 2ϩ sensitivity of the myofibrils. Because the phosphorylation state of troponin I is a major determinant of myofilament Ca 2ϩ sensitivity, the delicate balance between the protein kinases and protein phosphatases regulates myofibril Ca 2ϩ sensitivity (49). The regulation of troponin I phosphorylation is a complex process, involving the rates of protein expression, ␤-adrenergic signaling, PKA-and PKC-mediated troponin I phosphorylation, and PKA-and PKC-mediated modulation of protein phosphatase 1 activity (13, 48) . In the failing human heart, the dominant effects appear to be the downregulation of ␤-adrenergic signaling and the reduction in PKA-mediated troponin I phosphorylation (13, 48) . However, PKC assumes a more central role in the regulation of troponin I phosphorylation in the failing rodent heart, as the expression of several PKC isoforms increases, leading to enhanced phosphorylation of troponin I and reduced myofilament Ca 2ϩ sensitivity (13, 43, 48) . Among the PKC isoforms implicated in both ventricular remodeling and diminished myofilament Ca 2ϩ sensitivity is PKC-␦, which can phosphorylate troponin I at Ser23/Ser24, a site linked to reduced actin-myosin interactions and depressed contractile Fig. 7 . Effect of taurine depletion on the distribution of protein kinase C isoforms. Proteins were extracted from wild-type and TauTKO hearts using Tris buffer supplemented with EDTA, EGTA, protease inhibitors, and dithiothreitol. After several centrifugation steps, the pellet was suspended in buffer containing Triton X-100 and identified as the membrane fraction. The supernatant, which was identified as the cytosolic fraction, was obtained after a centrifugation step at 100,000 g. Western blots for the membrane and cytosolic fractions were obtained for the PKC␣, PKC␤2, PKC␦, PKCε, and PKC. The top panel shows representative gels of cytosolic and membrane samples of wild-type and TauTKO hearts. The bottom panel quantifies the relative values for each PKC isoform normalized to either GAPDH (cytosolic samples) or E-cadherin (membrane samples). Values shown represent means Ϯ SE of 4 -5 hearts. *Significant differences between wild-type and TauTKO hearts (P Ͻ 0.05).
function (43) . The TauTKO mouse heart mimics features of the rodent failing heart, as taurine deficiency is associated with an increase in both cytosolic and membrane levels of PKC-␦ and an increase troponin I phosphorylation, changes that reduce Ca 2ϩ sensitivity of the myofibrillar proteins. The weakening of Ca 2ϩ sensitivity of the myofibrillar proteins in the TauTKO heart favors improved myofibrillar relaxation. However, Ca 2ϩ transients of taurine deficient cardiomyocytes reveal delayed relaxation (38) , an effect usually attributed to reduced SR Ca 2ϩ handling. The observation that SR Ca 2ϩ ATPase activity declines in the TauTKO heart is consistent with other models of heart failure in which the reduction in SR Ca 2ϩ ATPase activity slows the removal of Ca 2ϩ from the cytosol and prolongs the relaxation phase of the heart.
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